Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults
- 1 August 2011
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 28 (8) , 635-649
Abstract
The introduction of targeted therapies has radically changed the treatment paradigm for metastatic renal cell carcinoma (mRCC). However, multiple clinical dilemmas have emerged. For instance, limited data are available to juxtapose the safety and efficacy profile of targeted therapies between older and younger adults. Herein, pivotal trials of vascular endothelial growth factor (VEGF)- and mammalian target of rapamycin (mTOR)-directed therapies are assessed in the context of their implications in treating older adults with mRCC. In general, subset analyses from these pivotal studies suggest similar efficacy of targeted therapies amongst older adults. Aging is accompanied by a multitude of physiological changes, as well as an increased prevalence of co-morbidities. The age-related toxicity profiles of targeted agents for mRCC are detailed to provide a framework for the risks and benefits of these therapies in older adults. Ultimately, tools such as the Comprehensive Geriatric Assessment (CGA) that account for physiological (as opposed to chronological) age may prove useful in the evaluation and treatment of older adults with mRCC.Keywords
This publication has 104 references indexed in Scilit:
- Breaking through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporation of BiomarkersMolecular Cancer Therapeutics, 2010
- EORTC elderly task force position paper: Approach to the older cancer patientEuropean Journal of Cancer, 2010
- Role of Age and Health in Treatment Recommendations for Older Adults With Breast Cancer: The Perspective of Oncologists and Primary Care ProvidersJournal of Clinical Oncology, 2008
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206Journal of Clinical Oncology, 2008
- Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized TrialJNCI: Journal of the National Cancer Institute, 2008
- Renal Cell Carcinoma in Young and Old Patients—Is There a Difference?Journal of Urology, 2008
- Overcoming challenges associated with chemotherapy treatment in the senior adult populationCritical Reviews in Oncology/Hematology, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007